Today's commercial applications for liquid biopsies are limited mainly to improving treatment selection for late-stage cancers. But that could be changing: The findings of a recent study bring the technology a step closer to the holy grail of cancer diagnostics—a pan-cancer screening test, capable of detecting multiple forms of cancer (especially those types that don't currently have screening tests) before symptoms would normally be reported.